GlobeNewsWire
06 Jul 2026, 10:50 UTC · 19w ago
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
Impact · against what's priced in
The FDA's acceptance of the NDA for deucrictibant IR is a positive catalyst for Pharvaris, establishing a concrete PDUFA date of April 23, 2027. Strong Phase 3 RAPIDe-3 data reduces the risk of regulatory failure for the on-demand treatment of HAE attacks.
- PHVS+0.60
No priced-in read yet





